CSR Earnings: Strong Backlog Shielding Sales From Housing Construction Slowdown; FVE Raised by 5%
We raise our fair value estimate for no-moat CSR CSR by 5% to AUD 5.80 per share, with shares screening roughly fairly valued. Despite a challenging housing construction backdrop, CSR’s building products business posted sales of AUD 1.009 billion in the first half of fiscal 2024, 11% above the previous corresponding period, or pcp. First-half building product EBIT reached a record AUD 165 million, up 18% year on year. Previously, we had factored in material volume declines for building products in fiscal 2024, reflecting the ongoing deterioration in detached dwelling approvals. But a strong backlog and an out-of-cycle price increase in the second half of fiscal 2023 have seen CSR’s sales decouple from the broader economic environment. We revise our near-term outlook accordingly.
With CSR’s building products segment looking much more resilient than originally anticipated, we now expect fiscal 2024 group sales to post a modest 1% fall on fiscal 2023, compared with a previous forecast of a sharp 13% decline. Although industry approvals for detached dwellings, which account for over half of building products revenue, are down 15% in the six months to September 2023 compared with the pcp, CSR’s pipeline is 50% above historical averages. This is set to drive activity well into calendar 2024, insulating CSR from the cyclical slowdown. Multiresidential construction, 17% of segment sales, also has a healthy pipeline of around two to three years of work. And approvals for nonresidential construction, 23% of sales, are at record levels, with particular strength in schools and health facilities.
Resilient volumes, combined with the out-of-cycle price increase, saw the operating margin for building products improve to 16.3% from 15.3% in the pcp, despite input cost pressures. We are now projecting a full-year building products EBIT margin of 14.9%, a 100-basis-point upgrade on our previous forecast and flat on fiscal 2023.
The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.